Erratum: Decline in US breast cancer rates after the women's health initiative: Socioeconomic and racial/ethnic differences. (American Journal of Public Health (2010) 100:S1 (S132-S139) doi: 10.2105/AJPH.2009.181628);Decline in US breast cancer rates after the Women's Health Initiative: Socioeconomic and racial/ethnic differentials

American Journal of Public Health

Volumn 100, Issue SUPPL. 1, 2010, Pages 972-

  Krieger, Nancy ^a   Chen, Jarvis T ^a   Waterman, Pamela D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER REGISTRY; ETHNOLOGY; FEMALE; HEALTH DISPARITY; HORMONE SUBSTITUTION; HUMAN; INFORMATION DISSEMINATION; MIDDLE AGED; PREVALENCE; RACE; REGISTER; SOCIAL CLASS; UNITED STATES;

AGED; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; FEMALE; HEALTH STATUS DISPARITIES; HORMONE REPLACEMENT THERAPY; HUMANS; INFORMATION DISSEMINATION; MIDDLE AGED; PREVALENCE; RECEPTORS, ESTROGEN; REGISTRIES; SEER PROGRAM; SOCIAL CLASS; UNITED STATES;

EID: 77950568381     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2009.181628e     Document Type: Erratum

References (66)

1. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton JL. Recent declines in hormone therapy utilization and breast; cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24(33): e49-e50.
2. Ravdin PM, Cronin KA, Howlader N, Chlebowski RT, Berry DA. A sharp decrease in breast cancer incidence in the United States in 2003. Presented at: 29th annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Available at: http://www.sabcs.org. Accessed February 8, 2007.
3. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-1674.
4. Clarke CA, Glaser SL. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control. 2007;18(8):847-852. (Pubitemid 47125116)
5. Hausauer AK, Keegan THM, Chang ET, Clarke CA Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype. Breast Cancer Res. 2007;9(6):R90.
6. Stewart SL, Sabatino SA, Foster SL, Richardson LC. Decline in breast cancer incidence-United States, 19992003. MMWR Morb Mortal Wkly Rep. 2007;56(22): 549-553.
7. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res. 2007;9(3):R28. (Pubitemid 350214681)
8. Glass G, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening, mammography, and estrogen receptor status. J Natl Cancer Inst. 2007; 99(15):1152-1161.
9. Bouchardy C, Morabia A, Verkooijen HM Fioretta G, Wespi Y, Schäfer P. Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer. 2006;6:78.
10. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilization of hormone replacement therapy. Breast Cancer Res Treat. 2008; 107(3):427-430. (Pubitemid 351172118)
11. Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet. 2008;372(9639):608-610.
12. Verkooijen HM, Koot VCM, Fioretta, G, et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat. 2008;107(3):389-395.
13. Parkin DM. Is the recent fall in incidence of postmenopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer. 2009; 45(9):1649-1653.
14. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone therapy in Australia. Med J Aust. 2008; 188(11):641-644.
15. Harsh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1): 47-53.
16. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140(3):184-188.
17. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Rev Med. 2005;118(12 suppl. 2):64S-73S.
18. Wei, F, Miglioretti DL, Connelly MT, et al. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monograph 2005;35: 106-112.
19. Rossouw RE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333.
20. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613.
21. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49-57.
22. Krieger N, Löwy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical and advocacy perspectives. J Epidemiol Community Health. 2005;59(9):740-748.
23. Friedman-Koss D, Crespo CJ, Bellantoni MF, Andersen RE. The relationship of race/ethnicity and social class to hormone replacement therapy: results from the Third National Health and Nutrition Examination Survey 1988-1994. Menopause 2002;9(4): 264-272.
24. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnidty and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97(6):439-448.
25. LawlorDA,DaveySmithG,EbrahimS. Sodoeconomicpositionandhormonereplacementtherapyuse: explainingthediscrepancyinevidencefromobservationandrandomizedcontrolledtrials. AmJPublicHealth.2004;94(12):2149-2154.(Pubitemid39578420)
26. Persson I, Bergkvist L, Lindgren C, Yuen J. Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol. 1997;50(5):611-618. (Pubitemid 27270211)
27. Surveillance Epidemiology and End Results (SEER) Program. Limited-Use Data (1973-2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission. Available at: http://seer.cancer.gov/data/index.html. Accessed August 3, 2009.
28. Surveillance Epidemiology and End Results (SEER) Program. Number of persons by race and Hispanic ethnicity for SEER participants (2000 census data). Available at: http://seer.canc.er.gov/regist.ries/data.html. Accessed August 3, 2009.
29. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Populations-Total US (1969-2005) -Linked To County Attributes-Total US 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released February 2008. Available at: http://seer.cancer.gov/ data/index.html. Accessed August 3, 2009.
30. US Census Bureau. Population estimates. Available at: http://www.census.gov/popest/estimates.php. Accessed August 3, 2009.
31. Clegg LX, Reidiman ME, Hankey BF, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 2007; 18(2):177-187.
32. Krieger N, Chen JT, Ware JH, Kaddour A. Race/ ethnicity and breast cancer estrogen receptor status: impact of class, missing data, & modeling assumptions. Cancer Causes Control 2008;19(10):1305-1318.
33. Surveillance Epidemiology and End Results (SEER) Program. County attributes. Available at: http://seer. cancer.gov/seerstat/variables/ countyattribs/index. html#ca2000. Accessed August 3, 2009.
34. Krieger N, Rehkopf DH, Chen JT, Waterman PD, Marcelu E, Kennedy M. The fall and rise of US inequities in premature mortality: 1960-2002. PLoS Med. 2008; 5(2):e46.
35. US Census Bureau American fact finder. Available at: http://fad:finder. census.gov/hoine/saff/main. html?-lang=en. Accessed August 3, 2009.
36. Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998;37(3).
37. Singh GK, Miller BA, Harikey BF, Edwards BK. Area Socioeconomic Variations in US Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975-1999. Bethesda, MD: National Cancer Institute; 2003. NIH publication 03-5417. NCI Cancer Surveillance Monograph Series No. 4.
38. Surveillance Research Program. National Cancer Institute SEER*Stat software, version 3.0. Available at: http://seer.cancer.gov/seerstat/index.html. Accessed August 3, 2009.
39. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer ratas. Stat Med 2000;19(3):335-351.
40. Kim H-J, Fay MP, Yu B, Barrett MJ, Feuer EJ. Comparability of segmented line regression models. Biometrics. 2004;60(4):1005-1014. (Pubitemid 40019042)
41. Krieger N, Chen JT, Ebel G. Can we monitor socioeconomic inequalities in health? A survey of U.S. Health Departments' data collection and reporting practices. Public Health Re 1997;112(6):481-491. (Pubitemid 127780241)
42. Krieger N, Chen JT, Waterman PD, Soobader M-J, Subramanian SV, Carson R. Geocoding and monitoring US socioeconomic, inequalities in mortality and cancer incidence: does choice of area-based measure and geographic level matter? The Public Health Disparities Geocoding Project. Am J Epidemiol 2002;156(5):471-482. (Pubitemid 34976986)
43. Subramanian SV, Jones K, Kaddour A, Krieger N. Revisiting Robinson: the perils of individualistic and ecologic fallacy. Int J Epidemiol. 2009;38(2):342-360.
44. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82(5):703-710.
45. Krieger N, Chen JT, Waterman PD, Rehikopf DH, Subramanian SV. Painting a truer pidure of US socioeconomic and radal/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health. 2005;95(2):312-323. (Pubitemid 40179832)
46. Rehkopf DH, Haughton L, Chen JT, Waterman PD, Subramanian SV, Krieger N. Monitoring socioeconomic disparities in death: comparing individual-level education and area-based socioeconomic measures. Am J Public Health 2006;96(12):2135-2138. (Pubitemid 44865103)
47. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17: 47-67.
48. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573-587.
49. SmigalC,JemalA,WardE,etal. Trendsinbreastcancerincidencebyraceandethnicity:update2006.CACancerJClin. 2006;56(3):168-183.(Pubitemid43847927)
50. Roberts H. Reduced use of hormones and the drop in breast cancer [editorial]. BMJ. 2009;338:b2116.
51. StaffordRS,SaglamD,CausinoN,BlumenthalD. Thedecliningimpactofraceandinsurancestatusonhormonereplacementtherapy.Menopause. 1998;5(3):140-144.(Pubitemid28425905)
52. BrettKM,MadansJH. DifferenceinuseofpostmenopausalhormonereplacementtherapybyBlackandWhitewomen. Menopause.1997;4(2):66-70.(Pubitemid127729498)
53. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270-282.
54. Cordera F, Jordan VC. Steroid receptors and their role in the biology and control of breast; cancer growth. Semin Oncol 2006;33(6):631-641. (Pubitemid 44834535)
55. Krieger N, Emmons K, Williams D. Defining, investigating, and addressing cancer inequities: critical issues. In: Koh H, ed. Toward the Elimination of Cancer Disparities: A Clinical and Public Health Perspective. New York, NY: Springer; 2009:3-28.
56. Trans-HHS Cancer Health Disparities Progress Review Group. Making Cancer Health Disparities History. Submitted to the Secretary, US Department of Health and Human Services, January 2004. Available at: http://www.hhs.gov/chdprg. Accessed February 8, 2007.
57. Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol. 2008;37(3):627-637. (Pubitemid 351804018)
58. Seaman B. The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth. New York, NY: Hyperion; 2003.
59. Petitti D. Commentary: hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol 2004;33(3):461,-463.
60. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science. 1993; 259(5095):633-638.
61. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer. 2000;7(2):73-83.
62. de Waard F, Thijssen JH. Hormonal aspects in the causation of human breast cancer: epidemiological hypotheses reviewed, with special reference to nutritional status and first pregnancy. J Steroid Biochem Mol Biol. 2005;97(5):451-458.
63. Tsubura A, Uehara N, Matsuoka Y, Yoshizawa K, Yuri T. Estrogen and progesterone treatment mimicking pregnancy for protection from breast cancer. In Vivo. 2008;22(2):191-201.
64. Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005;14(3);171-176.
65. Kunitz. S. The Health of Populations: General Theories and Particular Realities. Oxford, England: Oxford University Press; 2006.
66. Krieger N. Ways of asking and ways of living: reflections on the 50th anniversary of Morris' ever-useful Uses of Epidemiology. Int J Epidemiol 2007;36(6): 1173-1180. (Pubitemid 350238974)